Stock2740 wrote "I'm leaning to 18 month trial as sick patients increases Mace occurrence (sad but true the sick are helping our drug get to market )"

Not much of a stretch there, eh Stock? At least give credit where credit is due.

Anyone who watched the 9/25/15 corporate update heard Michael Sweeney and Kausik Ray explain that BETonMACE is modeled very similar to the EXAMINE trial, in which the 3-point MACE event rate in their patients was right around 10.5% at 18 months. BETonMACE is an event driven trial, with a goal of 250 events and a minimum of 2400 patients. 10.5% X 2400 patients gives you your 250 events at 18 months. Granted, the RVX-208 treatement arms are expected to have lower event rates. But as Michael Sweeney and Kausik Ray pointed out, BETonMACE will additionally have a low HDL (<45 mg/dL female, <40 mg/dl male) requirement that was not there for EXAMINE, so the average event rate for BETonMACE should actually be higher.